Group 1 - Tenaris S.A. filed its 2025 Annual Report with the Luxembourg Stock Exchange and the U.S. Securities and Exchange Commission (SEC) [1] - The 2025 Annual Report is available for download on both the Luxembourg Stock Exchange's website and Tenaris's website [2] - Tenaris will file its annual report on Form 20-F for the year ended December 31, 2025, with the SEC on March 31, 2026 [2] Group 2 - Holders of Tenaris's shares and ADSs can request a hard copy of the reports free of charge through the company's website [3] - The 2025 Annual Report includes a consolidated management report, consolidated financial statements, annual accounts, and management certifications [3] - Tenaris is recognized as a leading global supplier of steel tubes and related services for the energy industry and other industrial applications [3]

Core Viewpoint - TH International Limited, operating as Tims China, is set to release its fourth quarter and full year 2025 results on April 14, 2025, with a conference call scheduled for 8:00 AM EST [1]. Group 1 - Tims China is the exclusive operator of Tim Hortons coffee shops in mainland China, Hong Kong, and Macau [3]. - The company was founded by Cartesian Capital Group and Tim Hortons Restaurants International, a subsidiary of Restaurant Brands International [3]. - The conference call will be accessible via webcast on the company's website [1][4]. Group 2 - Participants are encouraged to pre-register for the conference call using the provided link [2]. - The company's operational philosophy emphasizes world-class execution, data-driven decision making, local relevance, continuous innovation, community engagement, and convenience [4].

Core Viewpoint - Alvotech has filed its Annual Report 2025 with the U.S. Securities and Exchange Commission, highlighting its commitment to transparency and regulatory compliance [1]. Company Overview - Alvotech is a biotechnology company focused on developing and manufacturing biosimilar medicines globally [2]. - The company aims to be a leader in the biosimilars market by providing high-quality, cost-effective products through a fully integrated approach and extensive in-house capabilities [2]. - Alvotech has five biosimilars approved and marketed in various global markets, including those for Humira®, Stelara®, Simponi®, Eylea®, and Prolia®/Xgeva® [2]. - The current development pipeline includes nine disclosed biosimilar candidates targeting autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [2]. - Alvotech has established strategic commercial partnerships to enhance its global reach and leverage local expertise across markets such as the United States, Europe, Japan, China, and parts of South America, Africa, and the Middle East [2].

Core Viewpoint - Alvotech has filed its Annual Report 2025 with the SEC, highlighting its commitment to transparency and regulatory compliance [1]. Company Overview - Alvotech is a biotechnology company focused on developing and manufacturing biosimilar medicines globally [2]. - The company aims to be a leader in the biosimilars market by providing high-quality, cost-effective products through a fully integrated approach [2]. - Alvotech has five biosimilars approved and marketed in various global markets, including those for Humira, Stelara, Simponi, Eylea, and Prolia/Xgeva [2]. - The current development pipeline includes nine disclosed biosimilar candidates targeting autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [2]. - Alvotech has established strategic commercial partnerships to enhance its global reach and leverage local expertise across multiple regions, including the U.S., Europe, Japan, China, and parts of South America, Africa, and the Middle East [2].

Core Viewpoint - Alvotech has published its Annual Report for 2025, highlighting its focus on the development and manufacture of biosimilar medicines, with a commitment to becoming a global leader in this sector [1]. Company Overview - Alvotech is a biotechnology company founded by Robert Wessman, dedicated to developing and manufacturing biosimilar medicines for patients worldwide [2]. - The company aims to deliver high-quality, cost-effective products and services through a fully integrated approach and broad in-house capabilities [2]. - Alvotech has five biosimilars approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept), and Prolia®/Xgeva® (denosumab) [2]. - The current development pipeline includes nine disclosed biosimilar candidates targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer [2]. - Alvotech has established a network of strategic commercial partnerships to enhance its global reach and leverage local expertise in various markets, including the United States, Europe, Japan, China, and parts of South America, Africa, and the Middle East [2].

Core Viewpoint - Caliber has successfully converted approximately $15.9 million of perpetual convertible preferred equity into common stock, streamlining its capital structure and reducing the amount of capital senior to its common stock [1][3]. Group 1: Transaction Details - An institutional investor converted 15,868 shares of Series B Preferred Stock, originally issued at $1,000 per share, into common stock at a conversion price of $250 per share, resulting in the issuance of 63,472 shares of common stock [2]. - The preferred equity was perpetual and carried no dividends, and the conversion effectively removes $15.9 million of preferred equity from the company's capital structure [2][3]. Group 2: Capitalization Summary - Before the conversion, Caliber had 6,618,768 shares of Class A common stock and 370,822 shares of Class B common stock. Post-conversion, the Class A common stock increased to 6,682,240 shares [4]. - The total stockholders' equity remained at $26,231,000 after the conversion, indicating a shift in the equity structure without altering the overall equity value [4]. Group 3: Company Overview - Caliber is a real estate-focused alternative asset manager with over $2.6 billion in managed assets and a 17-year track record in middle-market hospitality and multifamily real estate [5]. - The company has integrated digital asset infrastructure into its platform, investing in LINK, which supports real estate fund tokenization, and is implementing blockchain strategies to enhance asset financing and ownership [5].

Core Viewpoint - JD.com is proposing to offer CNY-denominated senior unsecured notes in offshore transactions to non-U.S. persons, subject to market conditions and other factors [1] Group 1: Notes Offering Details - The principal amount, interest rates, maturity dates, and other terms of the Notes will be determined at the time of pricing [1] - The net proceeds from the Notes Offering will be used for general corporate purposes, including repayment of existing indebtedness and payment of interest [2] - The Notes have not been registered under the Securities Act and cannot be offered or sold in the United States or to U.S. persons, except under certain exemptions [3] Group 2: Company Overview - JD.com is a leading supply chain-based technology and service provider, aiming to enable consumers to buy products whenever and wherever they want [6] - The company has opened its technology and infrastructure to partners and brands as part of its Retail as a Service offering, driving productivity and innovation across various industries [6]

Core Insights - Innovative Food Holdings, Inc. reported a revenue increase of 2.1% for fiscal year 2025, reaching $60.7 million compared to $59.4 million in 2024, despite a significant decline of 18.1% in Q4 2025 revenue compared to Q4 2024 [1][3] - The company experienced improvements in gross margin, which rose to 25.8% from 25.3% year-over-year [1] - The CEO emphasized a focus on operational assessment and repositioning to enhance growth consistency and reliability, particularly in digital channels [2][6] Financial Performance - For fiscal year 2025, GAAP net income from continuing operations was $2.5 million, down from $4.2 million in 2024, with a corresponding decrease in GAAP net income per diluted share from $0.081 to $0.046 [3][16] - Non-GAAP adjusted EBITDA for the year was $2.4 million, compared to $4.1 million in 2024, indicating a significant decline in operational profitability [3][22] - In Q4 2025, GAAP net income from continuing operations was $797 thousand, an increase from $685 thousand in Q4 2024, while non-GAAP adjusted EBITDA fell to $718 thousand from $1.3 million [1][3][22] Operational Developments - The company relocated its National Distribution operations from Pennsylvania to Chicago, which caused temporary disruptions but aimed to enhance service execution and operational alignment [3][4] - Local Distribution operations are stabilizing under new leadership, focusing on rebuilding customer relationships and improving service execution [5] - The company is prioritizing operational stabilization, systems modernization, and execution discipline as key objectives for 2026 [6] Strategic Initiatives - The company completed the sale of its Mountain Top, Pennsylvania facility for $9.225 million, using the proceeds to pay off the Maple Mark bank loan, which improved financial flexibility [1][6] - The CEO highlighted the importance of technology and process reliability as both a challenge and an opportunity for the company moving forward [6] - The company plans to selectively pursue growth opportunities that are operationally supportable and strategically aligned, focusing on stabilizing its core platform [6]

Core Viewpoint - Allbirds, Inc. has entered into a definitive agreement with American Exchange Group to sell its intellectual property and certain assets for an estimated transaction value of $39 million, marking a significant transition for the company [1][2]. Group 1: Transaction Details - The Asset Sale was approved unanimously by Allbirds' Board of Directors and is subject to stockholder approval, with a proxy statement expected to be filed by April 24, 2026 [2]. - The transaction is anticipated to close in the second quarter of 2026, with stockholders expected to receive net proceeds in the third quarter of 2026 after accounting for wind-down expenses [2]. Group 2: Company Background - Allbirds is recognized as a modern lifestyle footwear brand, founded in 2015, known for its commitment to innovative materials and superior comfort, with products inspired by nature [5]. - The company has evolved into a brand known for its modern design and customer engagement, with the CEO expressing gratitude for the team's efforts in building the brand [3]. Group 3: American Exchange Group Overview - American Exchange Group is a leader in fashion accessory products and brand management, focusing on distribution to major retailers and maintaining a consumer-centric approach for sustainable growth [6].

Core Insights - AleAnna, Inc. reported positive financial results for the fourth quarter and full year of 2025, achieving a net income of $2.9 million and an Adjusted EBITDA of $6.6 million, marking the third consecutive quarter of positive performance [1][2][3]. Financial Performance - In the fourth quarter of 2025, AleAnna generated $9.1 million in revenue, with $3.0 million of Adjusted EBITDA driven by strong production at the Longanesi field [3][8]. - The company recognized $8.5 million in revenue from its share of production from the Longanesi field during the fourth quarter [3]. - For the full year 2025, total revenues reached $25.0 million, significantly up from $1.4 million in 2024 [10][14]. Production and Operational Highlights - Daily production from the Longanesi field commenced in the second quarter of 2025, stabilizing at approximately 25-30 million cubic feet per day, exceeding the budgeted maximum production rate for 2025 [4][5]. - All five wells at the Longanesi field are currently contributing to production, indicating robust operational performance [4]. Management Commentary - CEO Marco Brun highlighted the fourth quarter as a significant milestone, emphasizing the strong performance from the Longanesi field and the company's commitment to exceeding expectations [5][6]. - The company is focused on advancing its growth strategy across both conventional and renewable natural gas, supported by a solid balance sheet and positive cash flow [6]. Strategic Positioning - AleAnna is positioned as a technology-driven energy company aiming to provide sustainable low-carbon natural gas and renewable natural gas in Italy, with multiple exploration projects planned for the decade [6]. - The company operates regional headquarters in Dallas, Texas, and Rome and Milan, Italy, leveraging Italy's extensive gas infrastructure to support its sustainability goals [6].